Femasys has received US Food and Drug Administration (FDA) clearance for its FemChec pressure management device, designed to deliver a low-pressure hysterosalpingography as a confirmation test following sterilisation surgery.

FemChec uses patent-pending technology that limits the applied intrauterine pressure to 200 mmHg, allowing physicians to meet the requirements of the mandatory hysterosalpingography confirmation test, while minimising improperly performed tests and procedure complications.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Femasys president and CEO Kathy Lee-Sepsick said the FemChec provides benefits to the physician and patient as a properly performed low-pressure confirmation test is critical to relying on the permanent sterilisation procedure long-term.

The company expects to market the first device in the US in December 2011.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact